Valuation as at 2026-08-14 · see also the ASX 300 Most Undervalued screen
About Fisher & Paykel Healthcare Corporation Limited
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
Fisher & Paykel Healthcare Corporation Limited FPH.AX
Healthcare · Medical Instruments & Supplies
Fisher & Paykel Healthcare Corporation Limited's price & financial trends
Annual reporting periods — this market does not have reliable quarterly data on Yahoo (either it isn't required, or coverage is incomplete), so annual is the most granular consistent series across free cash flow and dividends.
Data as at 2026-08-14
Share price · last 2 years
Earnings per share (diluted) Per year
Free cash flow Per year
Dividend per share Per year
Value investing scale · Buffett · Dalio · Graham
Intrinsic value estimate · 5-year forecast
Assumptions used in this valuation
Every input below is either fetched live from Yahoo Finance or a documented default — nothing is hidden.
| Bear | Base | Bull | |
|---|---|---|---|
| 5-yr FCF growth | 7.1% | 14.2% | 21.3% |
| Terminal growth | 2.5% | 2.5% | 2.5% |
| WACC (discount rate) | 11.12% | 10.12% | 9.12% |
Cost of Equity = Risk-free rate + Beta × Equity Risk Premium = 4.80% + 0.89 × 6.00% = 10.15% · WACC = weighted by 99%/1% capital structure
These numbers come from running Fisher & Paykel Healthcare Corporation Limited's cash flows through the mechanical DCF formula and assumptions above — not from any view on the news, management, or FPH.AX's competitive position. What is DCF?
Want to test your own growth or discount-rate assumptions?Open the full interactive calculator, pre-filled with FPH.AX →
More ASX stocks we've valued
Not financial advice. DCF valuations are highly sensitive to assumptions — small changes in growth rate or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Computed on 2026-08-14 from Yahoo Finance data, using the same engine as the full DCF tool and the ASX 300 Most Undervalued screen. Every figure above is a point-in-time snapshot of that date — change any assumption yourself in the interactive tool for a live one.
Frequently asked questions
Is Fisher & Paykel Healthcare Corporation Limited (FPH.AX) undervalued?
The Base-case DCF estimates intrinsic value at $12.60 vs a price of $35.43 on 2026-08-14 — a -64.4% margin, so the Base case reads overvalued. This is a mechanical output, not advice.